CA2501136A1 - Improved imaging agents comprising barbituric acid derivatives - Google Patents

Improved imaging agents comprising barbituric acid derivatives Download PDF

Info

Publication number
CA2501136A1
CA2501136A1 CA002501136A CA2501136A CA2501136A1 CA 2501136 A1 CA2501136 A1 CA 2501136A1 CA 002501136 A CA002501136 A CA 002501136A CA 2501136 A CA2501136 A CA 2501136A CA 2501136 A1 CA2501136 A1 CA 2501136A1
Authority
CA
Canada
Prior art keywords
imaging
radioactive
barbituric acid
group
imaging agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002501136A
Other languages
English (en)
French (fr)
Inventor
Klaus Kopka
Hans-Jorg Breyholz
Stefan Wagner
Michael Schafers
Bodo Levkau
Benedicte Guilbert
Duncan Wynn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2501136A1 publication Critical patent/CA2501136A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002501136A 2002-10-08 2003-10-08 Improved imaging agents comprising barbituric acid derivatives Abandoned CA2501136A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0223249.4A GB0223249D0 (en) 2002-10-08 2002-10-08 Improved imaging agents
GB0223249.4 2002-10-08
PCT/GB2003/004351 WO2004032936A1 (en) 2002-10-08 2003-10-08 Improved imaging agents comprising barbituric acid derivatives

Publications (1)

Publication Number Publication Date
CA2501136A1 true CA2501136A1 (en) 2004-04-22

Family

ID=9945439

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002501136A Abandoned CA2501136A1 (en) 2002-10-08 2003-10-08 Improved imaging agents comprising barbituric acid derivatives

Country Status (10)

Country Link
US (1) US20060120956A1 (https=)
EP (1) EP1549317A1 (https=)
JP (1) JP2006505550A (https=)
CN (1) CN1720050A (https=)
AU (1) AU2003273505B2 (https=)
CA (1) CA2501136A1 (https=)
GB (1) GB0223249D0 (https=)
NO (1) NO20051641L (https=)
RU (1) RU2005109272A (https=)
WO (1) WO2004032936A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
GB0612333D0 (en) * 2006-06-21 2006-08-02 Ge Healthcare Ltd Radiopharmaceutical products
CA2654369C (en) 2006-06-21 2014-10-14 Ge Healthcare Limited Radiopharmaceutical products
ATE551073T1 (de) * 2007-05-16 2012-04-15 Ge Healthcare As Markierte hgf-bindende peptide für bildgebung
GB0718386D0 (en) * 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
GB201115937D0 (en) 2011-09-14 2011-10-26 Univ Aberdeen 18F-labelled compounds for use as positron emission imaging agents
WO2020039088A2 (en) * 2018-08-24 2020-02-27 Xeniopro GmbH Novel compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952971A (en) * 1971-11-09 1976-04-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Airfoil shape for flight at subsonic speeds
US3952091A (en) * 1974-10-23 1976-04-20 Hoffmann-La Roche Inc. Simultaneous multiple radioimmunoassay
GB1527416A (en) * 1976-07-20 1978-10-04 Ciba Geigy Ag Photopolymerisible diepoxides
US6472227B1 (en) * 1986-06-04 2002-10-29 Abbott Laboratories Barbiturate assay, tracers, immunogens, antibodies and kit
US5102786A (en) * 1987-05-21 1992-04-07 Pb Diagnostic Systems, Inc. Biological diagnostic assay system
CA2332277A1 (en) * 1998-05-15 1999-11-25 Nycomed Amersham Plc Labelled glutamine and lysine analogues
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
WO2001092244A1 (en) * 2000-05-30 2001-12-06 Wayne State University Inhibitors of matrix metalloproteinases
IL154946A0 (en) * 2000-10-26 2003-10-31 Pfizer Prod Inc Pyrimidine-2,4,6-trione metalloproteinase inhibitors
BR0114913A (pt) * 2000-10-26 2003-07-01 Pfizer Prod Inc Inibidores de metaloproteinase de espiro-pirimidina-2,4,6-triona
CN100336521C (zh) * 2000-12-12 2007-09-12 血管实验室公司 蜜蜂花叶提取物制备抑制血管生成相关疾病药物的用途
GB0115929D0 (en) * 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase electrophilic fluorination

Also Published As

Publication number Publication date
CN1720050A (zh) 2006-01-11
WO2004032936A1 (en) 2004-04-22
AU2003273505B2 (en) 2007-04-19
AU2003273505A1 (en) 2004-05-04
GB0223249D0 (en) 2002-11-13
US20060120956A1 (en) 2006-06-08
NO20051641L (no) 2005-06-02
RU2005109272A (ru) 2006-01-27
EP1549317A1 (en) 2005-07-06
JP2006505550A (ja) 2006-02-16

Similar Documents

Publication Publication Date Title
JP5043438B2 (ja) 阻害剤造影剤
US20120244074A1 (en) Labelled integrin binders
US8506932B2 (en) Tetracyclic indole derivatives as in vivo imaging agents and having peripheralbenzodiazepine receptor affinity (PBR)
AU2004294784B2 (en) Novel imaging agents comprising caspase-3 inhibitors
AU2004210208B2 (en) Diagnostic imaging agents with MMP inhibitory activity
US20080279769A1 (en) Enzyme Inhibitor Imaging Agents
AU2003273505B2 (en) Improved imaging agents comprising barbituric acid derivatives
US20080292547A1 (en) Novel Imaging Agents for Fibrosis
CA2508663A1 (en) Labeled macrophage scavenger receptor antagonists for imaging cardiovascular diseases
WO2014122228A1 (en) Labelled compounds that bind to alpha-v-beta-3 integrin
US20080279771A1 (en) Novel Imaging Agents for Cancer

Legal Events

Date Code Title Description
FZDE Discontinued